@Zenox
Interesting comment and definitely possible given PAR's track record of taking us down endless rabbit holes.....
And if I was vetting their ASX releases I've remove an future reference to "key opinion leaders" until the can show their asset can be monetised
However, I'd also note the previous study referenced (Hennermann, 2016) dosage used: "PPS was applied subcutaneously in two patients with 1 mg/kg and in two patients with 2 mg/kg, weekly for 12 weeks and then biweekly for 12 weeks"
https://link.springer.com/article/10.1007/s10545-016-9974-5
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-22
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $207.3K | 1.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1903 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 15000 | 1 |
View Market Depth
| Last trade - 15.59pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |